Full Press Release Details
Marc Panoff, CFO Garth Russell / Todd Fromer
Nephros, Inc. KCSA Worldwide
Tel: 212-781-5113 212-896-1250 / 212-896-1215
NEPHROS, INC. TO PRESENT AT THE C.E. UNTERBERG TOWBIN
EMERGING GROWTH LIFE SCIENCES CONFERENCE ON OCTOBER 26TH
NEW YORK, October 19, 2005 -- Nephros, Inc. (AMEX: NEP), a medical device
company developing and marketing products used in the treatment of end-stage
renal disease (ESRD), announced today it will present at the C.E. Unterberg
Towbin Emerging Growth Life Sciences Conference. The Company is scheduled to
present at 2:20 p.m. Eastern Time on Wednesday, October 26th, at the Palace
Hotel in New York City.
Norman Barta, chief executive officer of Nephros, will present an overview of
the Company, including a review of its progress in developing and marketing its
Those not attending the conference will be able to listen to the presentation
live via webcast at www.nephros.com. An archived version of the webcast will be
available approximately one hour after the live presentation and can be accessed
until January 26, 2006.
Nephros, Inc., headquartered in New York, is a medical device company developing
and marketing products designed to improve the quality of life for the end-stage
renal disease (ESRD) patient, while addressing the critical financial and
clinical needs of the care provider. ESRD is a disease state characterized by
the irreversible loss of kidney function. Nephros believes that its products
remove a range of harmful substances more effectively, and more
cost-effectively, than existing treatment methods; particularly with respect to
substances known collectively as "middle molecules," due to their molecular
weight, that have been found to contribute to such conditions as carpal tunnel
syndrome, dialysis related amyloidosis, degenerative bone disease, and
ultimately, to mortality in the ESRD patient.
Forward-Looking Statements
This news release contains certain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995, as amended.
Such statements may include statements regarding the efficacy and intended use
of Nephros's technologies under development, the timelines for bringing such
products to market and the availability of funding sources for continued
development of such products and other statements that are not historical facts,
including statements which may be preceded by the words "intends," "may,"
"will," "plans," "expects," "anticipates," "projects," "predicts," "estimates,"
"aims," "believes," "hopes," "potential" or similar words. For such
statements, we claim the protection of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to various known
and unknown risks and uncertainties, many of which are beyond the control of
Nephros. Actual results may differ materially from the expectations contained in
the forward-looking statements. More detailed information about Nephros and the
risk factors that may affect the realization of forward-looking statements is
set forth in Nephros's filings with the Securities and Exchange Commission,
including Nephros's Annual Report on Form 10-KSB filed with the SEC for the
fiscal year ended December 31, 2004 and its Quarterly Report on Form 10-QSB
filed with the SEC for the fiscal quarter ended June 30, 2005. Investors and
security holders are urged to read those documents free of charge on the SEC's
web site at www.sec.gov. Nephros does not undertake to publicly update or revise
its forward-looking statements as a result of new information, future events or